A study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

Trial Identifier: D0818R00008
Sponsor: AstraZeneca
Collaborator:
Merck
NCTID:: NCT05775549
Start Date: July 2023
Primary Completion Date: October 2023
Study Completion Date: October 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, New York New York, US, 10032
US, New York New York, US, 10032
US, New York New York, US, 10032
US, New York New York, US, 10032
US, New York New York, US, 10032
US, New York New York, US, 10032
US, New York New York, US, 10032